Collaborative study for the establishment of erythropoietin BRP batch 4

Area of Science:

• Pharmacology and Pharmaceutical Sciences
• Biotechnology and Bioassay Development
• Regulatory Science and Standards

Background:

• The European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation (BRP) for erythropoietin (EPO) is crucial for in vivo bioassay potency determination.
• The previous BRP batch 3 stocks are depleted, necessitating the calibration of a replacement batch.
• A new Ph. Eur. Chemical Reference Substance (CRS) is available for physicochemical tests, but not for bioassays.

Purpose of the Study:

• To calibrate a new European Pharmacopoeia Biological Reference Preparation (BRP) for erythropoietin (EPO) as batch 4.
• To establish an International Unit (IU) calibrated replacement batch against the WHO 3rd International Standard for recombinant EPO.
• To validate the suitability of the candidate BRP (cBRP) for use in EPO potency determination via in vivo bioassays.

Main Methods:

• A collaborative study involving seven international laboratories was conducted.
• The candidate BRP (cBRP) was calibrated against the WHO 3rd International Standard (IS) for Erythropoietin, recombinant, for bioassay (11/170).
• In vivo bioassays, specifically normocythaemic and polycythaemic mouse methods, were employed as per the Ph. Eur. monograph (1316).

Main Results:

• The collaborative study confirmed the suitability of the candidate BRP (cBRP) for potency determination of EPO medicinal products.
• The European Pharmacopoeia Commission established the proposed standard as erythropoietin BRP batch 4 in November 2014.
• The assigned potency for BRP batch 4 is 13,000 IU/vial for use in specific mouse bioassays.

Conclusions:

• Erythropoietin BRP batch 4 is established as a reliable reference preparation for in vivo bioassays.
• The study ensured continuity of the International Unit (IU) by confirming the potency of the previous BRP batch 3 during the calibration.
• This new BRP batch supports the quality control and standardization of erythropoietin-based therapeutics.